It is one of the most promising healthcare companies in France. It is also part of French Tech 120, a support program for rapidly developing start-ups. Tissium, a young medical device company, is raising 50 million euros from international investors in order to get closer to its objective: to market its first product in 2023. It is a glue intended for use by surgeons to repair tissue. A way to avoid the use of screws or staples, traumatic for the patients.
“Our ambition is to change the way we reconstruct nerves and tissues in surgical procedures,”
says Christophe Bancel, CEO of Tissium.
Read also French
start-ups will create thousands of jobs in 2021
Christophe Bancel, younger brother of Stéphane, CEO of Moderna, co-founded the company in 2013. With a mother doctor and an engineer father, the tropism for health and innovation of the Bancel brothers owes nothing to chance.
Both are centralians.
Stéphane opted for
This article is for subscribers only.
You have 76% left to discover.
To cultivate one's freedom is to cultivate one's curiosity.
Keep reading your article for € 1 for 2 months
I ENJOY IT
Already subscribed?
Log in
/cloudfront-eu-central-1.images.arcpublishing.com/prisa/QZBKEHFL6RHI5FSPQNNBZGIIUA.jpg)
